ImClone/Bristol Aim To Expand Erbitux's Reach To Asia
This article was originally published in PharmAsia News
Executive Summary
ImClone and Bristol-Myers Squibb are attempting to make Erbitux (cetuximab) the first EGFR receptor-inhibiting monoclonal antibody to be available in Japan under a co-development and co-commercialization agreement with Merck KGaA announced Oct. 17
You may also be interested in...
Takeda Discontinues Involvement In Matuzumab After Phase II Failure
Takeda will no longer jointly pursue development of cancer monoclonal antibody matuzumab because the epidermal growth factor receptor antagonist failed to meet primary endpoints in a Phase II trial, the Osaka, Japan-based company announced Feb. 18
Takeda Discontinues Involvement In Matuzumab After Phase II Failure
Takeda will no longer jointly pursue development of cancer monoclonal antibody matuzumab because the epidermal growth factor receptor antagonist failed to meet primary endpoints in a Phase II trial, the Osaka, Japan-based company announced Feb. 18
Erbitux Approved As Monotherapy In Metastatic Colorectal Cancer Setting
Labeling for ImClone/Bristol’s epidermal growth factor receptor inhibitor is updated to include survival data as a single agent in colorectal cancer setting.